Search This Blog

Monday, April 28, 2025

Galmed Pharmaceuticals Signs Agreement for Novel Semaglutide Formulation

 

  • Galmed Pharmaceuticals partners with Entomus to develop a sublingual semaglutide formulation.
  • The new formulation offers a non-invasive alternative to existing semaglutide treatments, targeting expanding markets.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.